99mTc-HYNIC (Tyr3)-octreotide
Also known as: 99mTc-EDDA/HYNIC-TOC, 99mTc-HYNIC-(Tyr3)-octreotide, 99mTc-HYNIC-TOC, 99mTc‑HYNIC‑(Tyr3)‑octreotide, 99mTc‑HYNIC‑TOC, NeoTect, Tc-99m HYNIC-TOC, Tc-99m HYNIC‑TOC, Technetium-99m HYNIC‑Octreotide, Technetium‑99m labeled octreotide, Tektrotyd, TOC scintigraphy agent
Source 99mTc-HYNIC (Tyr3)-octreotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Technetium‑99m HYNIC‑(Tyr3)‑octreotide is a radiolabeled peptide used for SPECT imaging of somatostatin‑receptor positive tumors such as neuroendocrine neoplasms.
Mechanism of Action
high affinity binding to somatostatin receptor subtype 2 (SSTR2) on neuroendocrine tumor cells, enabling gamma‑camera imaging after technetium‑99m decay
Routes of Administration
Goals & Uses
- Detection of meningiomasDiagnostic OncologyModerate
- Staging and restaging of NETsDiagnostic OncologyHigh
- Detection of neuroendocrine tumors (NETs)Diagnostic OncologyHigh
- Staging of somatostatin‑receptor positive cancersDiagnosticModerate
- Detection of small cell lung cancerDiagnostic OncologyModerate
- SSTR2 expression assessmentDiagnosticModerate
- Assessment of somatostatin receptor expression prior to PRRTTreatment PlanningModerate
- Neuroendocrine tumor imagingDiagnosisModerate
- Imaging of neuroendocrine tumorsDiagnosticModerate
- Staging and localization of NETsDiagnosisHigh
Contraindications
- Hypersensitivity to octreotide or somatostatin analoguesAllergyHigh
- Known hypersensitivity to octreotide or excipientsImmunologicalModerate
- Severe renal impairmentOrganModerateKidney function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Known hypersensitivity to octreotide or technetium‑99m compoundsAllergyHigh
- Known hypersensitivity to octreotide or HYNICAllergyModerate
- BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
Adverse Effects
- Radiation exposureRadiologicalCommon
- Radiation exposure effectsRadiationCommon
- Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
- Hypersensitivity / anaphylaxisImmunologicalRare
- Injection site reactionsLocalUncommon
- Injection site painLocalCommonPain at the injection site
- HypotensionCardiovascularRareLow blood pressure
- Allergic reaction (urticaria, bronchospasm)ImmuneRare
- FlushingVascularUncommonWarmth and redness of the skin
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Hypoglycemia or hyperglycemiaMetabolicRare
- VomitingGastrointestinalRareForceful expulsion of stomach contents
- Injection site reactionLocalUncommonRedness, swelling, itching, bruising, or pain at the injection site
- Flushing or warmth sensationVascularCommon
Drug Interactions
- GlucocorticoidsLow
- Insulin and antidiabetic agentsLow
- Other somatostatin analogues (e.g., lanreotide)Moderate
- CorticosteroidsLow
- Interferon-alphaLow
- Long-acting somatostatin analogues (octreotide LAR, lanreotide)High
- Long-acting somatostatin analogs (octreotide LAR, lanreotide)Moderate
- Other radiopharmaceuticalsModerate
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Patients on long-acting somatostatin analoguesPharmacologicalRelative
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveRelative
- Pregnant womenReproductiveRelative
- Patients with severe renal impairmentOrgan ImpairmentRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionApprovedApproved: diagnostic imaging of somatostatin receptor positive tumorsMarketed under various trade names in EU member states.
- United StatesInvestigationalNot FDA‑approved; used in clinical trials.
- United KingdomUnknownNo specific MHRA approval identified post-Brexit; Ga-68–labeled agents are preferred in UK clinical practice.
Approved for diagnostic imaging in several EU member states; not FDA‑approved in the United States (investigational).
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is 99mTc-HYNIC (Tyr3)-octreotide?
Technetium‑99m HYNIC‑(Tyr3)‑octreotide is a radiolabeled peptide used for SPECT imaging of somatostatin‑receptor positive tumors such as neuroendocrine neoplasms.
What is 99mTc-HYNIC (Tyr3)-octreotide used for?
99mTc-HYNIC (Tyr3)-octreotide is educationally associated with: Detection of meningiomas, Staging and restaging of NETs, Detection of neuroendocrine tumors (NETs), Staging of somatostatin‑receptor positive cancers, Detection of small cell lung cancer, SSTR2 expression assessment, Assessment of somatostatin receptor expression prior to PRRT, Neuroendocrine tumor imaging, Imaging of neuroendocrine tumors, Staging and localization of NETs. Educational only — not medical advice.
How is 99mTc-HYNIC (Tyr3)-octreotide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of 99mTc-HYNIC (Tyr3)-octreotide?
Reported adverse effects include: Radiation exposure, Radiation exposure effects, Allergic reaction, Hypersensitivity / anaphylaxis, Injection site reactions, Injection site pain, Hypotension, Allergic reaction (urticaria, bronchospasm), Flushing, Nausea, Hypoglycemia or hyperglycemia, Vomiting, Injection site reaction, Flushing or warmth sensation. This list is not exhaustive — consult a qualified clinician.
Who should avoid 99mTc-HYNIC (Tyr3)-octreotide?
Recorded contraindications: Hypersensitivity to octreotide or somatostatin analogues, Known hypersensitivity to octreotide or excipients, Severe renal impairment, Pregnancy, Known hypersensitivity to octreotide or technetium‑99m compounds, Known hypersensitivity to octreotide or HYNIC, Breastfeeding. Consult a qualified clinician before use.